Constitute Delaying News Today

Delaying, denying, limiting, or refusing a drug or device inspection without a reasonable justification will result in a less than collegial...

We analyzed the warning letters that the FDA issued to pharmaceutical and biotech companies in FY2022. Several key trends emerged, including a...

We analyzed the warning letters that the FDA issued to pharmaceutical and biotech companies in FY2022. Several key trends emerged, including a...

The FDA published a number of draft and final guidance documents in 2022. In this e-book, we summarize the most important guidance documents related...

The U.S. Food and Drug Administration (FDA) has published the revised draft guidance “Circumstances that Constitute Delaying, Denying, Limiting, or…

The U.S. Food and Drug Administration (FDA) has published the revised draft guidance “Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device...

The FDA has released for public comment a proposed draft guidance, Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or...

On December 15, the U.S. Food and Drug Administration (FDA) issued a draft guidance, titled "Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection"...

On December 15, the U.S. Food and Drug Administration (FDA) issued a draft guidance, titled “Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device...

U.S. Food and Drug Administration FDA issued a draft guidance, titled Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection, which clarifies the types of behaviors the that FDA may find inappropriate under the FDCA.